AC 0100MA

Drug Profile

AC 0100MA

Alternative Names: AC 0100; AC 0100 Maleate; AC0010 MA

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator ACEA Biosciences
  • Developer ACEA Biosciences; Hangzhou ACEA Pharmaceutical Research
  • Class Antineoplastics; Heterocyclic compounds; Pyrimidines; Pyrroles
  • Mechanism of Action Apoptosis stimulants; Epidermal growth factor receptor antagonists; Mitogen-activated protein kinase inhibitors; Raf kinase inhibitors; Ras protein inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Phase I Lung cancer

Most Recent Events

  • 01 Nov 2016 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Recurrent, Second-line therapy or greater) in China (PO) (NCT03001609)
  • 01 May 2015 Phase-I/II clinical trials in Non-small cell lung cancer (Late-stage disease, Recurrent, Inoperable/Unresectable, Second-line therapy or greater) in USA (PO) (NCT02448251)
  • 18 Jul 2013 AC 0010MA is covered by patent protection in USA, European Union, Canada and China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top